Which has higher valuation and earnings, IVA or OGN?

Organon & Co. has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 186.65 -$400.67M N/A N/A Organon & Co. $6.22B 0.58 $187M $0.77 17.81

Does the media favor IVA or OGN?

In the previous week, Organon & Co. had 6 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Organon & Co. and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Organon & Co.'s score of 0.92 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GPCR or IVA?

Structure Therapeutics has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Structure Therapeutics N/A N/A -$141.20M -$1.00 N/A Inventiva $5.07M 186.65 -$400.67M N/A N/A

Is GPCR or IVA more profitable?

Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Structure Therapeutics N/A -26.12% -24.85% Inventiva N/A N/A N/A

Does the media favor GPCR or IVA?

In the previous week, Structure Therapeutics had 12 more articles in the media than Inventiva. MarketBeat recorded 14 mentions for Structure Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Structure Therapeutics' score of 0.04 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ARQT or IVA?

Arcutis Biotherapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcutis Biotherapeutics $376.07M 8.62 -$16.14M $0.21 122.85 Inventiva $5.07M 186.65 -$400.67M N/A N/A

Does the media refer more to ARQT or IVA?

In the previous week, Arcutis Biotherapeutics had 21 more articles in the media than Inventiva. MarketBeat recorded 23 mentions for Arcutis Biotherapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Arcutis Biotherapeutics' score of 0.74 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend IVA or RGC?

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 263.38%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts clearly believe Inventiva is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09 Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, IVA or RGC?

Regencell Bioscience has lower revenue, but higher earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 186.65 -$400.67M N/A N/A Regencell Bioscience N/A N/A -$3.58M N/A N/A

Is IVA or RGC more profitable?

Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A Regencell Bioscience N/A N/A N/A

Does the media favor IVA or RGC?

In the previous week, Inventiva and Inventiva both had 2 articles in the media. Inventiva's average media sentiment score of 1.45 beat Regencell Bioscience's score of 0.93 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer IVA or MOR?

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 263.38%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inventiva 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09 MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, IVA or MOR?

MorphoSys has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 186.65 -$400.67M N/A N/A MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A

Is IVA or MOR more profitable?

Inventiva has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Inventiva's return on equity of 0.00% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets Inventiva N/A N/A N/A MorphoSys -226.79% -694.31% -22.55%

Inventiva (IVA) Competitors

$4.57 -0.03 (-0.65%)

As of 12:22 PM Eastern

Compare

IVA vs. OGN, GPCR, ARQT, RGC, and MOR

Should you buy Inventiva stock or one of its competitors? Inventiva's main competitors and comparable companies include Organon & Co. (OGN), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), Regencell Bioscience (RGC), and MorphoSys (MOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Inventiva compare to Organon & Co.?

Inventiva (NASDAQ:IVA) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Organon & Co. had 6 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Organon & Co. and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Organon & Co.'s score of 0.92 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 263.38%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 16.88%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

Organon & Co. has a net margin of 3.41% compared to Inventiva's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Organon & Co.	3.41%	88.97%	6.03%

Organon & Co. has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	186.65	-$400.67M	N/A	N/A
Organon & Co.	$6.22B	0.58	$187M	$0.77	17.81

Summary

Organon & Co. beats Inventiva on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Structure Therapeutics has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$1.00	N/A
Inventiva	$5.07M	186.65	-$400.67M	N/A	N/A

Structure Therapeutics currently has a consensus price target of $110.91, indicating a potential upside of 108.89%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 263.38%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 32.0% of Inventiva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Structure Therapeutics had 12 more articles in the media than Inventiva. MarketBeat recorded 14 mentions for Structure Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Structure Therapeutics' score of 0.04 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market.

Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-26.12%	-24.85%
Inventiva	N/A	N/A	N/A

Summary

Inventiva beats Structure Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Inventiva compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Inventiva (NASDAQ:IVA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

19.1% of Inventiva shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Arcutis Biotherapeutics has a net margin of 6.15% compared to Inventiva's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Inventiva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Inventiva	N/A	N/A	N/A

In the previous week, Arcutis Biotherapeutics had 21 more articles in the media than Inventiva. MarketBeat recorded 23 mentions for Arcutis Biotherapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 1.45 beat Arcutis Biotherapeutics' score of 0.74 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.62	-$16.14M	$0.21	122.85
Inventiva	$5.07M	186.65	-$400.67M	N/A	N/A

Arcutis Biotherapeutics presently has a consensus price target of $35.57, indicating a potential upside of 37.88%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 263.38%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Summary

Inventiva beats Arcutis Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Regencell Bioscience?

Inventiva (NASDAQ:IVA) and Regencell Bioscience (NASDAQ:RGC) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Inventiva presently has a consensus price target of $16.56, indicating a potential upside of 263.38%. Given Inventiva's stronger consensus rating and higher possible upside, research analysts clearly believe Inventiva is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
Regencell Bioscience	N/A	N/A	N/A

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 0.1% of Regencell Bioscience shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 2.0% of Regencell Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Inventiva has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market. Comparatively, Regencell Bioscience has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Regencell Bioscience has lower revenue, but higher earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	186.65	-$400.67M	N/A	N/A
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A

In the previous week, Inventiva and Inventiva both had 2 articles in the media. Inventiva's average media sentiment score of 1.45 beat Regencell Bioscience's score of 0.93 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inventiva beats Regencell Bioscience on 8 of the 10 factors compared between the two stocks.

How does Inventiva compare to MorphoSys?

Inventiva (NASDAQ:IVA) and MorphoSys (NASDAQ:MOR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

MorphoSys has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	186.65	-$400.67M	N/A	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Inventiva currently has a consensus target price of $16.56, suggesting a potential upside of 263.38%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Inventiva had 2 more articles in the media than MorphoSys. MarketBeat recorded 2 mentions for Inventiva and 0 mentions for MorphoSys. Inventiva's average media sentiment score of 1.45 beat MorphoSys' score of 0.00 indicating that Inventiva is being referred to more favorably in the media.

Company	Overall Sentiment
Inventiva	Positive
MorphoSys	Neutral

Inventiva has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

19.1% of Inventiva shares are held by institutional investors. Comparatively, 18.4% of MorphoSys shares are held by institutional investors. 32.0% of Inventiva shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Inventiva has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Inventiva's return on equity of 0.00% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
MorphoSys	-226.79%	-694.31%	-22.55%

Summary

Inventiva beats MorphoSys on 12 of the 15 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IVA vs. The Competition

Export

Metric	Inventiva	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$945.29M	$11.72B	$6.98B	$13.03B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	N/A	783.86	269.56	25.24
Price / Sales	186.65	748.12	596.34	100.74
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	-20.71	10.74	13.02	6.32
Net Income	-$400.67M	$2.78B	$3.45B	$347.92M
7 Day Performance	-5.08%	-0.29%	0.69%	0.91%
1 Month Performance	3.55%	-0.17%	1.32%	0.89%
1 Year Performance	7.96%	160.95%	66.86%	20.28%

Inventiva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IVA Inventiva	2.9492 of 5 stars	$4.56 -1.0%	$16.56 +263.4%	+14.4%	$945.29M	$5.07M	N/A	100	Positive News
OGN Organon & Co.	1.5702 of 5 stars	$13.57 +0.0%	$11.40 -16.0%	+46.9%	$3.56B	$6.22B	17.62	10,000	News Coverage
GPCR Structure Therapeutics	2.1319 of 5 stars	$49.68 +2.7%	$110.55 +122.5%	+185.5%	$3.53B	N/A	N/A	136	Analyst Revision
ARQT Arcutis Biotherapeutics	4.1293 of 5 stars	$26.20 +1.0%	$34.00 +29.8%	+65.3%	$3.27B	$376.07M	N/A	150	Positive News Insider Trade
RGC Regencell Bioscience	0.2918 of 5 stars	$6.03 -1.7%	N/A	-61.0%	$2.98B	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inventiva (IVA) Competitors

IVA vs. OGN, GPCR, ARQT, RGC, and MOR

How does Inventiva compare to Organon & Co.?

Summary

How does Inventiva compare to Structure Therapeutics?

Summary

How does Inventiva compare to Arcutis Biotherapeutics?

Summary

How does Inventiva compare to Regencell Bioscience?

Summary

How does Inventiva compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inventiva (IVA) Competitors

IVA vs. OGN, GPCR, ARQT, RGC, and MOR

How does Inventiva compare to Organon & Co.?

Do insiders and institutionals have more ownership in IVA or OGN?

Does the media favor IVA or OGN?

Which has more risk and volatility, IVA or OGN?

Do analysts rate IVA or OGN?

Is IVA or OGN more profitable?

Which has higher valuation and earnings, IVA or OGN?

Summary

How does Inventiva compare to Structure Therapeutics?

Which has better valuation & earnings, GPCR or IVA?

Do analysts rate GPCR or IVA?

Do institutionals & insiders have more ownership in GPCR or IVA?

Does the media favor GPCR or IVA?

Which has more volatility and risk, GPCR or IVA?

Is GPCR or IVA more profitable?

Summary

How does Inventiva compare to Arcutis Biotherapeutics?

Do institutionals & insiders believe in ARQT or IVA?

Is ARQT or IVA more profitable?

Does the media refer more to ARQT or IVA?

Which has preferable valuation & earnings, ARQT or IVA?

Do analysts recommend ARQT or IVA?

Which has more volatility and risk, ARQT or IVA?

Summary

How does Inventiva compare to Regencell Bioscience?

Do analysts recommend IVA or RGC?

Is IVA or RGC more profitable?

Do insiders & institutionals believe in IVA or RGC?

Which has more volatility & risk, IVA or RGC?

Which has preferable valuation & earnings, IVA or RGC?

Does the media favor IVA or RGC?

Summary

How does Inventiva compare to MorphoSys?

Which has higher valuation and earnings, IVA or MOR?

Do analysts prefer IVA or MOR?

Does the media favor IVA or MOR?

Which has more volatility and risk, IVA or MOR?

Do insiders & institutionals have more ownership in IVA or MOR?

Is IVA or MOR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IVA vs. The Competition

Inventiva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools